Shares of Novavax Inc. (NASDAQ:NVAX) traded up 2.7% during mid-day trading on Monday . The company traded as high as $7.23 and last traded at $7.21, with a volume of 3,591,558 shares trading hands. The stock had previously closed at $7.02.

A number of analysts recently issued reports on the company. Chardan Capital reiterated a “neutral” rating on shares of Novavax in a report on Monday, May 2nd. Zacks Investment Research lowered Novavax from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Wedbush reiterated an “outperform” rating and issued a $14.00 price target on shares of Novavax in a report on Wednesday, May 25th. Finally, Vetr lowered Novavax from a “strong-buy” rating to a “buy” rating and set a $8.02 price target for the company. in a report on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Novavax presently has a consensus rating of “Buy” and a consensus target price of $11.05.

The company has a 50-day moving average price of $7.38 and a 200 day moving average price of $5.94. The firm’s market capitalization is $1.96 billion.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.04. During the same period in the prior year, the company earned ($0.08) EPS. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $8.03 million. Novavax’s revenue was down 82.1% on a year-over-year basis. On average, analysts forecast that Novavax Inc. will post ($1.07) EPS for the current fiscal year.

In other news, Director Gary C. Evans sold 18,998 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $6.50, for a total transaction of $123,487.00. Following the completion of the sale, the director now owns 321,979 shares in the company, valued at approximately $2,092,863.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary C. Evans sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $5.41, for a total transaction of $270,500.00. Following the sale, the director now owns 357,111 shares of the company’s stock, valued at approximately $1,931,970.51. The disclosure for this sale can be found here.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.